Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
26 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
84.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
34
34 articles ont été cités au moins 34fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
4 492
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
179
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
68
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
EURAMET.T-K9 regional key comparison ITS-90 SPRT calibration from the Ar TP to the Zn FP
2024ArticleMetrologia
Transcriptional landscape of human keratinocyte models exposed to 60-GHz millimeter-waves
2024ArticleToxicology in Vitro
Dementia with Lewy bodies and gait neural basis: a cross-sectional study
2024ArticleAlzheimer's Research and Therapy
Pneumonia-Associated Emergency Transfers, Functional Decline, and Mortality in Nursing Home Residents
2023ArticleJournal of the American Medical Directors Association
ITS-90 SPRT calibration from the Ar TP to the Zn FP
2023ArticleMetrologia
Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies
2022ArticleJAMA neurology
CSF in Epileptic Prodromal Alzheimer's Disease: No Diagnostic Contribution but a Pathophysiological One
2021ArticleFrontiers in Neurology
Effects of radiofrequency field exposure on proteotoxic-induced and heat-induced HSF1 response in live cells using the bioluminescence resonance energy transfer technique
2021ArticleCell Stress and Chaperones
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CABINET DU DR CATHERINE MARTIN
7 BOULEVARD PIERRE BROSSOLETTE, 02000 LAON
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Anesthesiology · 2024
Background High-dose corticosteroids have been used to attenuate the inflammatory response to cardiac surgery and cardiopulmonary bypass, but patient outcome benefits remain unclear. The primary aim was to determine whether using dexamethasone was superior to not using dexamethasone to increase the number of home days in the first 30 days after cardiac surgery. The secondary aim was to evaluate efficiency, value, and impact of the novel trial design. Methods This pragmatic, international trial incorporating a prerandomized consent design favoring local practice enrolled patients undergoing cardiac surgery across seven hospitals in Australia and The Netherlands. Patients were randomly assigned to dexamethasone 1 mg/kg or not (control). The primary outcome was the number of days alive and at home up to 30 days after surgery (“home days”). Secondary outcomes included prolonged mechanical ventilation (more than 48 h), sepsis, renal failure, myocardial infarction, stroke, and death. Results Of 2,562 patients assessed for eligibility, 1,951 were randomized (median age, 63 yr; 80% male). The median number of home days was 23.0 (interquartile range, 20.1 to 24.1) in the no dexamethasone group and 23.1 (interquartile range, 20.1 to 24.6) in the dexamethasone group (median difference, 0.1; 95% CI, –0.3 to 0.5; P = 0.66). The rates of prolonged mechanical ventilation (risk ratio, 0.72; 95% CI, 0.48 to 1.08), sepsis (risk ratio, 1.02; 95% CI, 0.57 to 1.82), renal failure (risk ratio, 0.94; 95% CI, 0.80 to 1.12), myocardial infarction (risk ratio, 1.20; 95% CI, 0.30 to 4.82), stroke (risk ratio, 1.06; 95% CI, 0.54 to 2.08), and death (risk ratio, 0.72; 95% CI, 0.22 to 2.35) were comparable between groups (all P > 0.10). Dexamethasone reduced intensive care unit stay (median, 29 h; interquartile range, 22 to 50 h vs. median, 43 h; interquartile range, 24 to 72 h; P = 0.004). The authors’ novel trial design was highly efficient (89.3% enrollment). Conclusions Among patients undergoing cardiac surgery, high-dose dexamethasone decreased intensive care unit stay but did not increase the number of home days after surgery. Editor’s Perspective What We Already Know about This Topic What This Article Tells Us That Is New
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024
Diabetes care · 2024
OBJECTIVE To describe the individual and joint associations of baseline factors with glycemia, and also with differential effectiveness of medications added to metformin. RESEARCH DESIGN AND METHODS Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants (with type 2 diabetes diagnosed for <10 years, on metformin, and with HbA1c 6.8–8.5%; N = 5,047) were randomly assigned to a basal insulin (glargine), sulfonylurea (glimepiride), glucagon-like peptide 1 agonist (liraglutide), or dipeptidyl peptidase 4 inhibitor (sitagliptin). The glycemic outcome was HbA1c ≥7.0%, subsequently confirmed. Univariate and multivariate regression and classification and regression tree (CART) analyses were used to assess the association of baseline factors with the glycemic outcome at years 1 and 4. RESULTS In univariate analyses at baseline, younger age (<58 years), Hispanic ethnicity, higher HbA1c, fasting glucose, and triglyceride levels, lower insulin secretion, and relatively greater insulin resistance were associated with the glycemic outcome at years 1 and/or 4. No factors were associated with differential effectiveness of the medications by year 4. In multivariate analyses, treatment group, younger age, and higher baseline HbA1c and fasting glucose were jointly associated with the glycemic outcome by year 4. The superiority of glargine and liraglutide at year 4 persisted after multiple baseline factors were controlled for. CART analyses indicated that failure to maintain HbA1c <7% by year 4 was more likely for younger participants and those with baseline HbA1c ≥7.4%. CONCLUSIONS Several baseline factors were associated with the glycemic outcome but not with differential effectiveness of the four medications. Failure to maintain HbA1c <7% was largely driven by younger age and higher HbA1c at baseline. Factors that predict earlier glycemic deterioration could help in targeting patients for more aggressive management.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Archives of disease in childhood · 2026 · Journal Article
Callahan KP, Dorner R, Jaworski M, Capaci L, et al.
Journal of the International AIDS Society · 2025 · Journal Article
Martin CE, Ramatsoma H, Chidumwa G, Cox LA, et al.
Emergency medicine Australasia : EMA · 2024 · Journal Article
Maleki S, Gu G, Buntine P, Zamani M, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024 · Journal Article
Bémer P, Aubry A, Schramm F, Koebel C, et al.
Military medicine · 2024 · Journal Article
Martin CL, Nocera M, Mercer J, Marshall SW, et al.
Antioxidants (Basel, Switzerland) · 2024 · Journal Article
Maalouly G, Martin CM, Baz Y, Saliba Y, et al.
HIV medicine · 2024 · Journal Article
Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, et al.
Emergency medicine Australasia : EMA · 2024 · Journal Article
Flacks N, Martin C, Liew D, Walker K, et al.
Immunotherapy · 2024 · Journal Article
Radhakrishnan S, Martin CA, Vij M, Subbiah K, et al.
Pediatric blood & cancer · 2026 · Journal Article
Zaman S, Schatz M, Kuhn AK, O'Keefe MB, et al.
Journal of pediatric hematology/oncology · 2026 · Journal Article
Greenmyer JR, Anderson ML, Cameron CS, Kranz LA, et al.
Pediatric blood & cancer · 2025 · Journal Article
Martin CE, Kohorst MA, Ferdjallah A, Madigan T, et al.
AIDS and behavior · 2025 · Journal Article
Martin CE, Muhwava LS, Dada S, Scorgie F, et al.
JACC. Advances · 2025 · Journal Article
Sedding D, Schmidt TM, Bähre H, Bavendiek U, et al.
Anesthesiology · 2024 · Journal Article
Myles PS, Dieleman JM, Munting KE, Forbes A, et al.
Diabetes care · 2024 · Randomized Controlled Trial
Garvey WT, Cohen RM, Butera NM, Kazemi EJ, et al.
The Journal of cardiovascular nursing · 2026 · Journal Article
Martin CM, Algashgari EY, Lu Y, Stewart JC, et al.
The Australasian journal of dermatology · 2025 · Journal Article
Jegathees T, Holmes ZP, Martin C, Kalai C, et al.
Addictive behaviors · 2024 · Meta-Analysis
Abufarsakh B, Okoli CTC, Darville AK, Williams LB, et al.
Anesthesiology · 2024 · Journal Article
Myles PS, Dieleman JM, Munting KE, Forbes A, et al.
Diabetes care · 2024 · Randomized Controlled Trial
Garvey WT, Cohen RM, Butera NM, Kazemi EJ, et al.
Diabetes care · 2024 · Randomized Controlled Trial
Hollander PA, Krause-Steinrauf H, Butera NM, Kazemi EJ, et al.
International journal of surgery (London, England) · 2026 · Journal Article
Gurunathan U, Smith S, Dillon S, Pulle RC, et al.
The lancet. HIV · 2026 · Journal Article
Martin CE, Ramatsoma H, Chidumwa G, Nongena P, et al.
The Australasian journal of dermatology · 2025 · Journal Article
Jegathees T, Holmes ZP, Martin C, Kalai C, et al.
Addictive behaviors · 2024 · Meta-Analysis
Abufarsakh B, Okoli CTC, Darville AK, Williams LB, et al.
Journal of geriatric oncology · 2025 · Journal Article
Theodoulou E, Martin C, Morgan J, Turner O, et al.
Cureus · 2024 · Case Reports
Arce MI, Breetz KA, Martin CA
Enhanced Reading of Travel Accounts with the SIMILE Exhibit Widget
Preferences, educational messaging, and demand creation channels for multipurpose-prevention technologies (MPTs) among women in South Africa
Abstract Background South African women, including female sex workers (FSWs), are disproportionately affected by HIV, experience a high unmet need for contraception and high rates of sexually transmitted infections (STIs
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
International journal of language & communication disorders · 2025 · Journal Article
Pennington L, Potts L, Murray J, Geytenbeek J, et al.
Pediatric blood & cancer · 2024 · Case Reports
Martin CE, Kuhn AK, Leopold KN, Creo AL, et al.